Short interest for Otsuka Holdings gives investors a sense of the degree to which investors are betting on the decline of Otsuka Holdings's stock. Short interest data is updated every two weeks.

Otsuka Holdings Stock (OTC:OTSKY), Short Interest Report

OTSUKA HOLDINGS CO.

Otsuka Holdings

Otsuka Holdings Co Ltd is a Japan-based company operates in pharmaceuticals, nutraceuticals and consumer products. Business activity of the company includes providing healthcare solutions in the areas of nervous system, oncology, cardiovascular system, respiratory system, infectious disease and others. It is also engaged in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks and dietary food. In addition it also operates multiple businesses related to chemicals, transportation, warehousing, and electronic equipment. Geographically, it operates in Japan, North America and in other regions of which Japan accounts for larger share of revenue.

cannabis CGC TLRY

Biotech

Cannabis

News

Health Care

OTSKF

OTSKY

IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer&#39;s agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer&#39;s-Associated Agitation

dementia-Photo by Gerd Altmann via Pixabay

Movers

Trading Ideas

General

IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer&#39;s Dementia. Shows reduction in agitation vs. placebo observed.

Alzheimer&#39;s-Focused Small Cap Firm IGC Pharma Releases Data,  Candidate Reduces Agitation Compared To Placebo

One Year Into Kabir Nath’s Leadership, Compass Pathways’ (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing 

Small Cap

CMPS

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by persistent symptoms of depression that do not respond adequately to at least two different standard antidepressant treatments.

One Year Into Kabir Nath&#39;s Leadership, Compass Pathways&#39; (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

OTSUKA HOLDINGS CO ADR by Otsuka Holdings Co. Ltd.

Otsuka Holdings Co Ltd

While Roivant Sciences (ROIV) has been seeing stable revenue growth, its bottom line is in the red. So, will it be worth owning ROIV now? Let's discuss some of its key financial metrics to gauge its prospects... Roivant Sciences Ltd. (<a href="https://stocknews.com/stock/ROIV/">ROIV</a>) continues to advance its clinical programs, expanding possibilities within the realm of autoimmune therapies. In terms of financial performance, the company posted a substantial increase in revenue, climbing to $37.10 million for the fiscal second quarter ended September 2023.
However, on the bottom line, it recorded a wider net loss for the same period of $331.12 million. This equates to a net loss per common share of $0.40. On the plus side, the company's non-GAAP net losses exhibited a minor drop, falling to $225.39 million from $226.79 million year-on-year.
On the insider activity front, Eric Venker, the COO of ROIV, executed consecutive sales of 500,000 shares in September and 1,200,000 in October. Over the past year, the insider has sold an aggregate of 4,204,309 shares without any purchases. Insider selling at Roivant Sciences Ltd has been frequent, with 42 sell-off and just one purchase over the past year. These transactions may point to a potential lack of confidence in the company's future prospects among insiders.
As such, it may be prudent to evaluate the company's key financial metrics before making a decision. The current circumstance may suggest that this is not an ideal time to enter the stock. Let's analyze some of its key financial metrices.
Analyzing ROIV's Financial Performance: A Three Year Trend Overview from 2020 to 2023
Based on the trailing-12-month Net Income of ROIV, the company has been experiencing a trend of increasing net losses over the course of three years. Given the data set:
<ul>
<li>As of December 31, 2020, ROIV started at a relatively low net loss of -$10.77 million.</li>
<li>On March 31, 2021, the company registered a significant rise in net loss to -$809.23 million.</li>
<li>The company saw further deterioration by the end of the third quarter of 2021, with netinc standing at -$1.099 billion.</li>
<li>There was a slight decrease in the company's net loss by December 31, 2021, reporting -$556.18 million.</li>
<li>Despite the decrease in the last quarter of 2021, ROIV's net loss escalated again to -$845.26 million as of March 31, 2022.</li>
<li>By the end of September 2022, ROIV's net loss slightly rose to -$1.178 billion.</li>
<li>As of December 31, 2022, the net loss reached its peak at -$1.245 billion.</li>
<li>In the first three quarters of 2023, there was a mild reduction in the company's net loss from -$1.009 billion in March 31 to -$981.77 million by September 30.</li>
</ul>
Overall, ROIV's net income registered decreased income over these years, indicating the company's deteriorating financial health. The figure has exploded from -$10.77 million in December 31, 2020 to -$981.77 million in September 30, 2023, showing a substantial increase in negative growth.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1700587298.16932.png" />
Here is a summary of the trailing-12-month revenue trends and fluctuations for ROIV from December 2020 to September 2023:
<ul>
<li>From December 2020 to March 2021, the Revenue was at $0.</li>
<li>Significant growth began in the second quarter of 2021. By the end of March 2021, the Revenue reached $23.80 million.</li>
<li>Substantial increment continued through 2021, ending the year with $46.06 million in Revenue by December 2021.</li>
<li>The trend varied in 2022, with an initial increase of Revenue to $55.29 million by March, followed by a slight decline to $51.87 million by June, and then further decrease to $50.42 million by September. The Revenue fell to its lowest point for the year at $43.13 million in December.</li>
<li>In 2023, a rebound occurred starting with $61.28 million in March, and a significant incline to $78.59 million in Revenue by June.</li>
<li>The most substantial increase noted during the period was in September 2023, with the Revenue reaching a peak of $103.15 million.</li>
</ul>
Overall, ROIV's Revenue has seen a remarkable net growth between December 2020 and September 2023, despite some fluctuations in 2022. This highlights a progressively upward trajectory, particularly noticeable in the year 2023.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1700587333.50135.png" />
<ul>
<li>In March 2021, ROIV reported a substantially low <a href="https://www.investopedia.com/terms/r/returnonassets.asp">ROA</a> of -3.92.</li>
<li>Towards the end of the same year, on December 31, 2021, there was a significant improvement in ROIV's ROA as it increased to -0.254.</li>
<li>However, beginning from the year 2022, the company's ROA gradually declined through each quarter. By the end of 2022, on December 31, it had fallen to -0.519.</li>
<li>In 2023, there was a minor improvement in ROA at -0.429 in the first quarter of the year; however, any gains were quickly lost as ROIV's ROA continued on a downward trajectory for the remainder of the year, achieving -0.447 by the end of September 2023.</li>
</ul>
Overall, the company's ROA showed a negative growth rate from -3.92 in March 2021 to -0.447 by September 2023. Notwithstanding a brief improvement towards the end of 2021, ROIV has been demonstrating a consistent decrease in its ROA over the given time series. The recent data indicates a continued decline with no immediate signs of reversal.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1700587430.90064.png" />
The Current Ratio of ROIV has shown both upward and downward trends from December 2020 to September 2023. Key Observations:
<ul>
<li>The Current Ratio of ROIV started at 3.58 in December 2020, and then it dramatically increased to 9.99 in March 2021.</li>
<li>However, a sharp drop is observed as the ratio decreased to 0.40 in subsequent months of 2021.</li>
<li>In June 2021, the current ratio rebounded to 9.83, before experiencing a slow decline over the next two quarters and closing the year (December 2021) at 14.23, the highest value in the observed period.</li>
<li>From there, the ratio declined steadily until reaching 6.74 by the end of December 2022, followed by a mild fluctuation that resulted in a consistent downturn in 2023 with a brief uptick seen in September 2022 (7.43).</li>
<li>By the end of the observation period in September 2023, the Current Ratio had decreased to 5.84, a significant decrease compared to its peak in December 2021.</li>
</ul>
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1700587453.43334.png" />
Analyzing ROIV's Share Price Fluctuation: A 180-Day Journey from May to November 2023
The data provided shows the share price of ROIV from May 26, 2023 until November 20, 2023. Here is an overview: -
<ul>
<li>On May 26, 2023, ROIV shares were priced at $9.23.</li>
<li>In June 2023, they saw a gradual increase from $9.22 to $9.86.</li>
<li>On July 07, 2023, they saw a significant jump to $10.43. This upward trend continued until July 21, 2023, when the share value reached $11.54, indicating a strong growth rate during July.</li>
<li>However, towards the end of July 2023, the price fell slightly to $10.97, and the fluctuation continued into August 2023: the share price rose to $11.79 early in August 2023 but dipped back to $10.98 by August 18, 2023.</li>
<li>Starting September, the prices showed a volatile trend and peaked at $11.97 on September 29, 2023.</li>
<li>Starting October 2023, there was a notable downward trend. Beginning at a price of $10.42, the shares lost value each week, ending at $8.71 by October 27.</li>
<li>November 2023 saw less fluctuation compared to previous months, with the overall trend being slight recuperation in the share price, peaking at $9.09 before falling again to close out the period on November 20, 2023, at a price of $8.85.</li>
</ul>
Overall, shares of ROIV experienced periods of both growth and decline between May and November 2023. From a macroscopic view, it seems that after a major growth spike in the summer, particularly July, the stocks faced a decelerating trend starting October 2023. Here is a chart of ROIV's price over the past 180 days.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1700587587.67105.png" />
Examining Trends in ROIV's Growth, Sentiment and Value Across 2023
ROIV has an overall D rating, translating to a Sell in our <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> system. It is ranked #177 out of the 345 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> category.
Analyzing the POWR Ratings of ROIV across six dimensions, the three most noteworthy are: Growth, Sentiment, and Value.
Growth:
<ul>
<li>In May 2023, the Growth dimension was rated at 67.</li>
<li>There was a notable upward trend over the next few months, increasing to 84 by September 2023.</li>
<li>Since then, the Growth rating has remained relatively stable, marginally decreasing to 83 by November 2023.</li>
</ul>
Sentiment:
<ul>
<li>The Sentiment score showed a remarkable surge in the middle of the period, reaching a high of 97 in July 2023.</li>
<li>However, this peak was followed by a downward trend, with ratings going from 92 in August and September to 70 in November 2023.</li>
</ul>
Value:
<ul>
<li>The Value score for ROIV also observed a rising trajectory.</li>
<li>Starting at just 13 points in May 2023, there was a threefold increase to 42 points in September 2023.</li>
<li>It thereafter slightly dipped, sitting at 41 points throughout October and November 2023.</li>
</ul>
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1700587644.14073.png" />
How does Roivant Sciences Ltd. (ROIV) Stack Up Against its Peers?
Other stocks in the Biotech sector that may be worth considering are Incyte Corporation (<a href="https://stocknews.com/stock/INCY">INCY</a>), Otsuka Holdings Co Ltd (<a href="https://stocknews.com/stock/OTSKY">OTSKY</a>), and Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX">VRTX</a>) -- they have better POWR Ratings.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
ROIV shares were trading at $8.67 per share on Tuesday afternoon, down $0.13 (-1.48%). Year-to-date, ROIV has gained 8.51%, versus a 19.74% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Subhasree Kar</h2> <img src='https:/wp-content/uploads/2021/06/Subhasree-Kar-HS2.jpg' style="float:left; padding:5px;width:125px;">Subhasree's keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master's degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics.<a href="https://stocknews.com/authors/?author=subhasree-kar">More...</a>The post <a href=https://stocknews.com/news/roiv-incy-otsky-vrtx-is-roivant-sciences-roiv-the-right-biotech-stock-for-your/>Is Roivant Sciences (ROIV) the Right Biotech Stock for Your Portfolio?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Roivant Sciences (ROIV) the Right Biotech Stock for Your Portfolio?

New ADHD drugs could pay off for pharmaceutical companies

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn my view… Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>) is scheduled to report its fourth-quarter and full-year results on February 6. Wall Street expects the biotech major to post lower revenue on a year-over-year basis, while its EPS is expected to increase. In this piece, I have discussed why it could be wise to buy the stock now despite the potential decline in revenue.
For the fourth quarter, GILD's EPS is expected to increase 5.5% year-over-year to $1.76. However, its revenue for the same quarter is expected to decline 3.9% year-over-year to $7.10 billion.
The company reported solid earnings and revenue during the third quarter. GILD's Chairman and CEO, Daniel O'Day, said, "Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by both Virology and Oncology."
"Our clinical momentum also remains strong, and highlights this quarter included new data on Trodelvy with pembrolizumab in first-line metastatic non-small cell lung cancer. In Virology, we completed enrollment for Phase 3 trials of lenacapavir for HIV prevention and oral obeldesivir for COVID-19. We are looking forward to advancing these and other potential new options for patients over the coming months," he added.
For the full year, GILD expects total product sales to come between $26.70 billion and $26.90 billion, compared to $26.30 billion and $26.70 billion previously. Its total product sales, excluding Veklury, are estimated to come between $24.80 billion and $25 billion, compared to the previously expected $24.60 billion and $25 billion. The company expects Veklury sales to come in at $1.90 billion, compared to the previous estimate of $1.70 billion.
Additionally, its non-GAAP EPS is expected between $6.65 and $6.85, compared to the previous estimates of $6.45 and $6.80. The company's current expectation for Acquired IPR&amp;D (In-process research and development) is approximately $350 million.
On October 17, 2023, GILD and Assembly Biosciences, Inc. (<a href="https://stocknews.com/stock/ASMB/">ASMB</a>) announced that the companies have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio's established areas of herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). GILD will provide Assembly Bio with $100 million upfront, including a $15.2 million equity investment.
There will be an impact of approximately $0.05 and $0.07 on its fourth-quarter GAAP and non-GAAP EPS. On December 19, 2023, GILD announced an agreement with Compugen to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. The agreement will have an impact of between $0.03 and $0.05 on its fourth-quarter GAAP and non-GAAP EPS.
Similarly, GILD announced the expansion of its partnership with Arcellx, Inc. ACLX will receive a $200 million equity investment from GILD, which will raise GILD's ownership in the company to 13%. In addition, GILD will make a non-dilutive cash payment of $85 million. Impact on the fourth quarter GAAP and non-GAAP EPS will be approximately between $0.09 and $0.11.
Over the past six months, GILD's stock has gained 1.7% to close the last trading session at $76.96.
Here's what you might want to consider ahead of its upcoming earnings release:
Robust Financials
GILD's total revenues for the fiscal third quarter ended September 30, 2023, rose marginally year-over-year to $7.05 billion. Its product sales increased marginally over the prior-year quarter to $7 billion. The company's non-GAAP net income attributable to GILD increased 20.4% year-over-year to $2.88 billion.
Also, its non-GAAP EPS came in at $2.29, representing an increase of 20.5% year-over-year. In addition, its cash and cash equivalents at the end of the period increased 21.4% year-over-year.
Mixed Analyst Estimates
Analysts expect GILD's EPS and revenue for fiscal 2023 to decline 6.9% and 0.7% year-over-year to $6.76 and $27.08 billion, respectively. On the other hand, its EPS and revenue for fiscal 2024 are expected to increase 6.4% and 2% year-over-year to $7.19 and $27.63 billion, respectively.
Discounted Valuation
In terms of forward non-GAAP P/E, GILD's 11.39x is 39.2% lower than the 18.74x industry average. Its 8.51x forward EV/EBITDA is 36.1% lower than the 13.31x industry average. Likewise, its 10.45x forward EV/EBIT is 37.5% lower than the 16.72x industry average.
High Profitability
In terms of the trailing-12-month gross profit margin, GILD's 78.81% is 37.6% higher than the 57.28% industry average. Likewise, its 42.85% trailing-12-month EBITDA margin is 735.4% higher than the industry average of 5.13%. Furthermore, the stock's 0.44x trailing-12-month <a href="https://www.investopedia.com/terms/a/assetturnover.asp">asset turnover ratio</a> is 12.4% higher than the industry average of 0.39x.
POWR Ratings Show Promise
GILD has an overall A rating, equating to a Strong Buy in our proprietary <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> system. The POWR Ratings are calculated considering 118 distinct factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. GILD has an A grade for Value, consistent with its discounted valuation.
It has a B grade for Quality, which is in sync with its high profitability.
GILD is ranked #4 out of 349 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/GILD/">Click here</a> to access GILD's Growth, Momentum, Stability, and Sentiment ratings.
Bottom Line
GILD has major plans to become a significant force in the oncology field, with its Trodelvy drug leading the charge. The company has set an ambitious goal of achieving a third of its revenue from oncology products by 2030. Its cell therapies, Yescarta and Tecartus, are also expected to keep boosting its topline.
Meanwhile, its HIV sales continue to impress, with Biktarvy and Descovy seeing robust demand. Biktarvy is expected to grow strongly in the fast-growing infectious disease market.
Considering these factors and given its robust financials, discounted valuation, and high profitability, it could be wise to buy the stock now.
How Does Gilead Sciences, Inc. (GILD) Stack Up Against Its Peers?
While GILD has an overall grade of A, equating to a Strong Buy rating, you may also check out these other A (Strong Buy) or B (Buy)-rated stocks within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry: Incyte Corporation (<a href="https://stocknews.com/stock/INCY/">INCY</a>), Otsuka Holdings Co., Ltd. (<a href="https://stocknews.com/stock/OTSKY/">OTSKY</a>), and United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>). To explore more Biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
GILD shares fell $0.32 (-0.42%) in premarket trading Monday. Year-to-date, GILD has declined -5.39%, versus a 3.75% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Dipanjan Banchur</h2> <img src='https:/wp-content/uploads/2021/11/Dipanjan-Banchur_headshots_3.jpg' style="float:left; padding:5px;width:125px;">Since he was in grade school, Dipanjan was interested in the stock market. This led to him obtaining a master's degree in Finance and Accounting. Currently, as an investment analyst and financial journalist, Dipanjan has a strong interest in reading and analyzing emerging trends in financial markets.<a href="https://stocknews.com/authors/?author=dipanjan-banchur">More...</a>The post <a href=https://stocknews.com/news/gild-incy-otsky-uthr-asmb-gilead-gild-quarterly-earnings-buy-or-sell-signal/>Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Drug manufacturer Amgen Inc. (AMGN) is actively pursuing strategic collaborations and making noteworthy strides in the realm of obesity treatments. With the company all set to lift the curtains on its fiscal fourth-quarter earnings tomorrow, would it be prudent to take a bullish stance on the stock now? Keep reading to find out… Boasting a strong market cap of $172.96 billion, Amgen Inc. (<a href="https://stocknews.com/stock/AMGN/">AMGN</a>) specializes in the discovery, development, manufacturing, and distribution of human therapeutics worldwide. The company's extensive product portfolio is dedicated to addressing diverse medical needs, spanning oncology, cardiovascular disease, and bone health.
AMGN is slated to announce its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024. Analysts project a significant 18.5% year-over-year growth for revenue to reach $8.11 billion in the fourth quarter. Similarly, the company's EPS for the same quarter is expected to climb 12.3% year-over-year to $4.59.
Meanwhile, during the third quarter, the company exhibited resilience, as reflected by upticks in both revenue and adjusted profits. Robert A. Bradway, the chairman and chief executive officer of AMGN, conveyed enthusiasm regarding the progress of the pipeline and the operational performance achieved in the third quarter.
Additionally, AMGN solidified its position as a leading healthcare provider across a wider spectrum of diseases with the acquisition of Horizon Therapeutics plc on October 6, 2023. By harnessing Horizon's assets, AMGN aims to deliver innovative medications that significantly benefit patients grappling with severe illnesses.
On top of it, AMGN is strategically positioning itself to tap into the lucrative obesity market segment. Forecasts indicate that the obesity market is poised to <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-plot-way-into-obesity-market-with-deals-development-2024-01-11/">exceed $100 billion</a> by the end of the decade, fueled by consumer demand for treatments capable of reducing weight by up to 20%.
Given the solid demand, the drug maker is currently making <a href="https://www.pharmaceutical-technology.com/analyst-comment/amgen-obesity-space-jpm24/?cf-view&amp;cf-closed">advancements in the obesity space</a>, with two therapies in its pipeline. Maridebart cafraglutide, previously known as AMG-133, is currently undergoing Phase II trials and the other therapy, AMG-786, is in Phase I trials. Also, AMGN is actively pursuing the development of six additional obesity medicines in the preclinical stage.
Furthermore, on December 12, 2023, AMGN declared a quarterly dividend of $2.25 per share, payable to its shareholders on March 7, 2024. The company's annual dividend of $9 translates to a 2.78% yield on the prevailing price, while its four-year average dividend yield is 2.98%. Its dividend payouts have grown at a CAGR of 10% over the past three years. In addition, the company has a record of 12 years of consecutive dividend growth.
AMGN's shares have rallied 40.3% over the past six months and 21.2% over the past three months to close the last trading session at $323.19.
Here are the fundamental aspects of AMGN that could influence its performance in the near term:
Strong Financials
AMGN's total revenue for the fiscal third quarter (ended September 30, 2023) increased 3.8% year-over-year to $6.90 billion, while its non-GAAP operating income rose 3.8% from the prior-year quarter to $3.40 billion.
Moreover, the company's non-GAAP net income and non-GAAP EPS came in at $2.68 billion and $4.96, up 5.4% and 5.5% from the year-ago value, respectively. During the same quarter, its total current assets stood at $48.48 billion, increasing 118.5% compared to $22.19 billion as of December 31, 2022.
Upbeat Analyst Estimates
The consensus revenue estimate of $28.11 billion for the fiscal year ending December 2023 represents a 6.8% improvement year-over-year. Meanwhile, the consensus EPS estimate of $18.54 for the same period reflects a 4.8% year-over-year surge.
Robust Profitability
AMGN's trailing-12-month EBIT and levered FCF margins of 36.15% and 33.19% are significantly higher than the 0.16% and 0.13% industry averages, respectively. Its trailing-12-month Return On Common Equity (ROCE) of 133.80% compares to the industry average of negative 42.25%. Furthermore, the stock's trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a> of 49.57% is 823.3% higher than the 5.37% industry average.
POWR Ratings Exhibit Solid Prospects
AMGN's robust fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by accounting for 118 distinct factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. AMGN has an A grade for Quality justified by its higher-than-industry profitability metrics. Moreover, the stock's B grade for Stability is consistent with its 24-month beta of 0.47.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, AMGN is ranked #12 out of the 349 stocks.
Beyond what we've stated above, we have also rated the stock for Growth, Value, Momentum, and Sentiment. Get all AMGN ratings <a href="https://stocknews.com/stock/AMGN/">here</a>.
Bottom Line
AMGN is fortifying its position in the healthcare industry through significant acquisitions. Moreover, despite being a late mover in the obesity space, AMGN's ongoing innovations hold the potential to be highly profitable for the company.
Additionally, the company's attractive dividend yield, strong third-quarter performance, and optimistic analyst estimates further bolster AMGN's appeal as an investment candidate. Therefore, as AMGN gears up to disclose its fourth quarter results tomorrow, it might be an opportune time to scoop up the company's shares for potential gains.
How Does Amgen Inc. (AMGN) Stack Up Against Its Peers? 
While AMGN has an overall grade of A, equating to a Strong Buy rating, you may also check out these other stocks within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry: Incyte Corporation (<a href="https://stocknews.com/stock/INCY/">INCY</a>), Otsuka Holdings Co., Ltd. (<a href="https://stocknews.com/stock/OTSKY/">OTSKY</a>), and Corcept Therapeutics Incorporated (<a href="https://stocknews.com/stock/CORT/">CORT</a>), carrying A (Strong Buy) ratings. To explore more Biotech stocks, click <a href="https://stocknews.com/category/biotech/">here</a>.  
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
AMGN shares were trading at $319.92 per share on Monday morning, down $3.27 (-1.01%). Year-to-date, AMGN has gained 11.08%, versus a 3.47% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Mukherjee</h2> <img src='https:/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg' style="float:left; padding:5px;width:125px;">Anushka's ultimate aim is to equip investors with essential knowledge that empowers them to make well-informed investment choices and attain sustained financial prosperity in the long run.<a href="https://stocknews.com/authors/?author=anushka-mukherjee">More...</a>The post <a href=https://stocknews.com/news/amgn-incy-otsky-cort-amgn-earnings-spotlight-analyzing-potential-gains/>AMGN Earnings Spotlight: Analyzing Potential Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

AMGN Earnings Spotlight: Analyzing Potential Gains

Warning: OTSKY is at high risk of cutting its dividend

Vertex Pharma upgraded at Evercore on Alpine Immune deal

Artisan Global Equity Fund Q1 2024 Commentary

Otsuka Holdings GAAP EPS of ¥142.59, revenue of ¥519.52B; reaffirms FY24 outlook

AIIXY

AIQUF

AIQUY

AIXXF

ALPN

AMGN

ASMB

AXSM

BAESF

BAESY

CALT

CING

CLTEF

CORT

DSKYF

DSNKY

EADSF

EADSY

GILD

INCY

KELRF

MDIBF

MDIBY

MLSPF

MNXBF

MSCI

MTSFF

MTSFY

NFLX

NONOF

NSRGF

NSRGY

NTRA

NVDA

NVSEF

ROIV

RSNHF

RYAAY

RYAOF

SAFRF

SAFRY

TOKUF

TOKUY

TOYOF

TUIFF

TVTX

TYNPF

UCBJF

UCBJY

UTHR

VERA

VRTX

WMMVF

WMMVY

One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing